Indonesia and Vietnam medical devices markets: size, growth and outlook 2026–2032

Fast-growing markets with government e-catalogues and local-content rules. Published estimates normalised to 2025 range from USD 1.8 bn to USD 3.2 bn; the Consulting Wallah central estimate is USD 4.9 bn, growing at about 8% a year to USD 8.1 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by indonesia: JKN universal coverage and USD 4 bn IHSS hospital equipment programme (SIHREN USD 1.8 bn, SOPHI USD 1.1 bn, InPULS USD 0.6 bn); indonesia: TKDN local-content policy cut import share of e-catalogue from 92% to 52%; local production grew to USD 3.37 bn (2025 est.); vietnam: market USD 1.9 bn (2024) growing 8.2% to USD 2.8 bn by 2029 (BMI); health spend >USD 22 bn.

Context that matters for buyers and suppliers: Indonesia 2025 est.: local production USD 3.37 bn, imports USD 1.91 bn, exports USD 2.50 bn, market USD 2.78 bn (ASPAKI/ITA). Indonesia e-catalogue import share fell from 92% to 52% after 2022 TKDN regulation; 16,777 local vs 56,325 imported devices listed in 2025. Indonesia Kemenkes registry: 75.8% AKL (imported), 24.2% AKD (domestic); China 36.5% of imports; Class B 45.1%. Indonesia: 42% of device registrations (33,059) expire in 2026-2027.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 1.8 bn–USD 3.2 bn; differences are mostly scope.

Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Indonesia 2025 est.: local production USD 3.37 bn, imports USD 1.91 bn, exports USD 2.50 bn, market USD 2.78 bn (ASPAKI/ITA) (US ITA)
• Indonesia e-catalogue import share fell from 92% to 52% after 2022 TKDN regulation; 16,777 local vs 56,325 imported devices listed in 2025 (US ITA)
• Indonesia Kemenkes registry: 75.8% AKL (imported), 24.2% AKD (domestic); China 36.5% of imports; Class B 45.1% (MedDeviceGuide)
• Indonesia: 42% of device registrations (33,059) expire in 2026-2027 (MedDeviceGuide)
• Indonesia imports led by China, then US, Germany, South Korea, Japan (US ITA)
• Vietnam imports ~90% of medical equipment; government hospitals buy 86% of market (US ITA)
• Vietnam Decree 98/2021 effective 1 Jan 2022 moved registration to post-inspection with Class A-D; IMDA registers Class C/D, provinces notify A/B; CSDT format mandatory for C/D from 1 Jan 2024 (US ITA; MedDeviceGuide)
• Vietnam register: 108,658 valid registrations, 21,871 applicants; Roche Vietnam largest (2.39%); top 10 only 9.1% (MedDeviceGuide)
• Vietnam private hospitals: 384 (24% of hospitals, 5.8% of beds); healthcare spend >USD 22 bn (4.7% GDP) in 2024 (US ITA)

Where the GCC and India sit

• Indonesia import share of e-catalogue listings: fell from 92% to 52% since 2022 TKDN rules (2025) — US ITA
• Indonesia MoH e-catalogue listings: 16,777 local vs 56,325 imported devices (2025) — US ITA
• Indonesia hospitals: 3,155 (1,181 public, 1,974 private) (2023) — US ITA
• Indonesia IHSS procurement programme (SIHREN, SOPHI, InPULS): USD 4 bn across 73 bidding packages (2023-2025) — US ITA
• Vietnam import dependence: ~90% of medical equipment imported (2026) — US ITA
• Vietnam healthcare expenditure: > USD 22 bn (4.7% of GDP) (2024) — BMI via US ITA

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: indonesia local manufacturing/assembly to qualify for e-katalog TKDN preference and USD 4 bn IHSS packages; indonesia expiry cliff (33,059 registrations expiring 2026-2027) opens re-registration and switching window; vietnam Class C/D registration via ASEAN CSDT format since Jan 2024 eases regional dossier reuse.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers and exporters: registration first, local partner second, tender readiness third — see what GCC buyers need.
• Hospital leaders: total cost of ownership (service, consumables, software) outweighs purchase price; tender the bundle.
• Investors: local assembly and distribution platforms backed by procurement preference.

1. US International Trade Administration, Indonesia Country Commercial Guide - Healthcare, Medical Devices & Equipment — trade.gov
2. MedDeviceGuide, Indonesia's Device Registry: 78K Registrations, 76% Imported, Expiry Cliff — meddeviceguide.com
3. MedDeviceGuide, Indonesia e-Katalog Medical Device Procurement Guide — meddeviceguide.com
4. US International Trade Administration, Vietnam Country Commercial Guide - Healthcare — trade.gov
5. MedDeviceGuide, Vietnam MOH Medical Device Register Analysis 2026 — meddeviceguide.com
6. US International Trade Administration (Country Commercial Guide, ASPAKI data) (2025-11) — USD 2.99 bn (2025 est. USD 2.78 bn) (2024) to — (), CAGR —; scope: country / Indonesia; market = local production + imports - exports; 2025 est. local production USD 3.37 bn, imports USD 1.91 bn, exports USD 2.50 bn — source
7. MedDeviceGuide (citing US Commercial Service) (2026-06) — USD ~2.78 bn (2025) to — (), CAGR —; scope: country / Indonesia medical devices — source
8. BMI Research (cited by US ITA) (2026-03) — USD 1.9 bn (2024) to USD 2.8 bn (2029), CAGR 8.2% (2024-2029); scope: country / Vietnam medical devices — source
9. MedDeviceGuide (2026-06) — USD ~1.7 bn (8th largest in APAC) (2024) to USD ~2.5 bn (2029), CAGR mid-to-high single digit; scope: country / Vietnam medical devices — source
10. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
11. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.